Skip to main content

Advertisement

SpringerLink
Log in

Immunohistochemical Expression of ER, PR and HER2/neu in Endometrial Carcinoma

  • Original Article
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Background

Endometrial carcinoma (EC) is the third common gynecologic cancer in India. It consists of two major histological types: the most common endometrioid or type I EC and non-endometrioid or type II EC. They are biologically distinct, and various markers have been proposed as prognostic biomarkers in EC besides clinical and pathological features.

Objectives

To study the immunohistochemical (IHC) expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2/neu) in EC and to correlate them with various clinicopathological parameters.

Methods

IHC study of ER, PR and HER2/neu was performed on 35 cases of histopathologically diagnosed EC in hysterectomy specimens for a period of 4 years from 2014 to 2017.

Results

Majority of the patients were aged 51–60 years, and the common comorbid conditions were type 2 diabetes mellitus, hypertension and obesity. Histologically, 31 (88.57%) cases were of type 1 EC and 4 (11.43%) were of type II EC; in type II EC, 2 (5.7%) cases were papillary serous carcinoma and the remaining two cases each were malignant mixed Mullerian tumor (MMMT) and dedifferentiated carcinoma (DC). ER expression was observed in 29 cases (82.9%) and was statistically significant with tumor stage, tumor grade, histological type and intraglandular necrosis. PR expression was seen in 22 (62.9%) cases and showed significant association with tumor grade, myometrial invasion and histological type. HER2/neu was expressed in one case.

Conclusion

Establishing the diagnosis of molecular subtype of EC with limited markers, namely ER/PR, HER2/neu expression similar to breast cancer, may be useful to determine the treatment and prognosis, especially in developing countries. Studies with larger sample sizes may elucidate their role, which was the limitation in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  1. Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta analysis. World J Surg Oncol. 2015;13:208–19. https://doi.org/10.1186/s12957-015-0619-1.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: aclinicopathological study. Asian Pac J Cancer Prev. 2010;11(1):215–20.

    PubMed  Google Scholar 

  3. Maheshwari A, Kumar N, Mahantshetty U. Gynecological cancers: a summary of published Indian data. South Asian J Cancer. 2016;5(3):112–20.

    Article  Google Scholar 

  4. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, et al. A HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100(1):89–95.

    Article  CAS  Google Scholar 

  5. Wilczyński M, Danielska J, Wilczyński J. An update of the classical Bokhman’s dualistic model of endometrial cancer. PrzMenopauzalny. 2016;15(2):63–8.

    Google Scholar 

  6. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrialcancer. Lancet. 2016;387(10023):1094–108.

    Article  Google Scholar 

  7. Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device- delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.

    Article  CAS  Google Scholar 

  8. Longacre TA, Broaddus R, Chuang LT, Cohen MB, Jarboe EA, Mutter GL, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med. 2017;141(11):1508–12.

    Article  Google Scholar 

  9. Woo JS, Apple SK, Sullivan PS, Rao JY, Ostrzega N, Moatamed NA. Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience. Diagn Pathol. 2016;11(1):102.

    Article  Google Scholar 

  10. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–78.

    Article  CAS  Google Scholar 

  11. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol. 1988;6(7):1076–87.

    Article  CAS  Google Scholar 

  12. Kalogiannidis I, Petousis S, Bobos M, Margioula-Siarkou C, Topalidou M, Papanikolaou A, et al. HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. Arch Gynecol Obstet. 2014;290(6):1231–7.

    Article  CAS  Google Scholar 

  13. Binder PS, Mutch DG. Update on prognostic markers for endometrial cancer. Womens Health. 2014;10(3):277–88.

    CAS  Google Scholar 

  14. Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 1999;86(10):2083–9.

    Article  CAS  Google Scholar 

  15. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(3):744–51.

    Article  Google Scholar 

  16. Ellenson LH, Pirog EC. The female genital tract. In: Kumar V, Abbas AK, Aster JC (eds) Pathologic basis of disease, 9th edn. Philadelphia: Elsevier Saunders; pp 1014–18.

    Chapter  Google Scholar 

  17. Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, et al. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control. 2016;27(6):737–48.

    Article  Google Scholar 

  18. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310.

    Article  CAS  Google Scholar 

  19. Lapińska-Szumczyk S, Supernat A, Majewska H, Gulczyński J, Luczak A, Biernat W, et al. HER2-positive endometrial cancer subtype carries poor prognosis. Clin Transl Sci. 2014;7(6):482–8.

    Article  Google Scholar 

  20. Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014;50(17):3003–10.

    Article  CAS  Google Scholar 

  21. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100(1):89–95.

    Article  CAS  Google Scholar 

  22. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER),and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98(3):383–9.

    Article  CAS  Google Scholar 

  23. Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124(1):15–20.

    Article  Google Scholar 

  24. Al-Loh S, Al-Hussaini M. Undifferentiated endometrial carcinoma: a diagnosis frequently overlooked. Arch Pathol Lab Med. 2013;137(3):438–42.

    Article  CAS  Google Scholar 

  25. Mylonas I. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep. 2010;24:385–93.

    Article  Google Scholar 

  26. Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2013;130(3):463–9.

    Article  CAS  Google Scholar 

  27. Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, et al. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1(ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol. 2013;44(6):1047–54.

    Article  CAS  Google Scholar 

  28. Buza N, Roque MD, Santin AD. HER2/neu in endometrial cancer-a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014;138:343–50.

    Article  Google Scholar 

  29. Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, Sensu S, et al. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol. 2010;5:13.

    Article  Google Scholar 

  30. Obeidat BR, Matalka II, Mohtaseb AA, Al-Kaisi NS. Selected immunohistochemicalmarkers in curettage specimens and their correlation with finalpathologic findings in endometrial cancer patients. Pathol Oncol Res. 2013;19(2):229–35.

    Article  CAS  Google Scholar 

  31. Suthipintawong C, Wejaranayang C, Vipupinyo C. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. J Med Assoc Thai. 2008;91(12):1779–84.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VSSIMSAR, Sambalpur, Odisha, India

    Kaustav Mohapatra

  2. JSS Medical College, #367, Adarsha, 6th Cross, Kamakshi Hospital Road, Kuvempunagar, Mysore, 570009, India

    Sheela devi C. Shivalingaiah

Authors
  1. Kaustav Mohapatra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheela devi C. Shivalingaiah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheela devi C. Shivalingaiah.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohapatra, K., Shivalingaiah, S.C. Immunohistochemical Expression of ER, PR and HER2/neu in Endometrial Carcinoma. Indian J Gynecol Oncolog 17, 54 (2019). https://doi.org/10.1007/s40944-019-0298-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-019-0298-x

Keywords

Search

Navigation